# PF-08046054

Source: https://onco.cc/drugs/pf-08046054/  
OnCo record `pf-08046054` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PF-08046054 is an experimental antibody-drug conjugate from Pfizer in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.

## Summary

PF-08046054 is an antibody-drug conjugate developed by Pfizer. Its target is PD-L1 (the sponsor names PD-L1). ClinicalTrials.gov describes the intervention as: Antibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07144280 (A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)), in non-small-cell lung cancer. The largest, NCT07144280, plans to enrol 680 participants with primary completion expected 2028-03-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: SGN-PDL1V
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Antibody-drug conjugate directed at PD-L1, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of PF-08046054: https://clinicaltrials.gov/search?intr=PF-08046054

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- trials: [A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-4/), [Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers](https://onco.cc/trials/nct07227298/)

---
JSON: https://onco.cc/api/v1/entities/pf-08046054.json